Get the Stockscreener App
1.065
11.57%
-0.145
After Hours:
1.06
-0.005
-0.47%
An 2 Therapeutics Inc stock is traded at $1.065, with a volume of 798.74K.
It is down -11.57% in the last 24 hours and down -13.71% over the past month.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
See More
Previous Close:
$1.21
Open:
$1.21
24h Volume:
798.74K
Relative Volume:
5.35
Market Cap:
$32.14M
Revenue:
-
Net Income/Loss:
$-60.70M
P/E Ratio:
-0.5221
EPS:
-2.04
Net Cash Flow:
$-61.05M
1W Performance:
-8.55%
1M Performance:
-13.71%
6M Performance:
-35.93%
1Y Performance:
-47.55%
1-Day Range:
$1.01
$1.2101
1-Week Range:
$1.01
$1.2199
52-Week Range:
$0.87
$3.07
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Compare ANTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.065 | 35.91M | 0 | -60.70M | -61.05M | -2.04 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-03-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-02-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-12-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-12-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-12-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
View All
An 2 Therapeutics Inc Stock (ANTX) Latest News
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease - Business Wire
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors - Yahoo Finance
Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data - Business Wire
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - Yahoo Finance
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Yahoo Finance
PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
PTC Therapeutics, Inc. Announces Results from the Phase 2 PIVOT-HD Study of PTC518 in Stage 2 and Stage 3 Huntington's Disease Patients - marketscreener.com
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - The Victoria Advocate
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - GlobeNewswire
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire
Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - Yahoo Finance
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - Yahoo Finance
Protara's Bladder Cancer Drug TARA-002 Phase 2 Trial: 12-Month Efficacy Data Reveal Coming at Major Conference - Stock Titan
TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum - Stock Titan
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance
Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire
Cyrano Therapeutics Completes Enrollment in Phase 2 FLAVOR Trial of CYR-064 for Post-Viral Smell Loss - Yahoo Finance
KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 - GlobeNewswire
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study - MarketScreener
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewswire
NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - The Malaysian Reserve
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - Yahoo Finance
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in the - GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewswire
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study - Benzinga
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - Yahoo Finance
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Yahoo Finance
Yoda Therapeutics Announces First Patient Dosed in Phase 2 Trial of YA-101 for Multiple System Atrophy - BioSpace
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Yahoo Finance
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Quantisnow
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - Stock Titan
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - Yahoo Finance
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - The Manila Times
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
An 2 Therapeutics Inc Stock (ANTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Day Lucy | Chief Financial Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
32,670 |
| Chanda Sanjay | Chief Development Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
29,824 |
| Prior Stephen David | Chief Strategy Officer |
Jan 03 '25 |
Sale |
1.34 |
2,029 |
2,721 |
33,313 |
| Eizen Joshua M | See Remarks |
Jan 03 '25 |
Sale |
1.34 |
9,663 |
12,958 |
116,672 |
| Readnour Robin Shane | Director |
Dec 09 '24 |
Buy |
1.43 |
30,772 |
43,984 |
647,573 |
| Readnour Robin Shane | Director |
Dec 06 '24 |
Buy |
1.45 |
19,228 |
27,795 |
629,090 |
| Readnour Robin Shane | Director |
Dec 10 '24 |
Buy |
1.49 |
10,000 |
14,930 |
652,573 |
| Readnour Robin Shane | Director |
Nov 27 '24 |
Buy |
1.42 |
50,000 |
70,840 |
622,573 |
| Readnour Robin Shane | Director |
Nov 26 '24 |
Buy |
1.39 |
25,000 |
34,845 |
597,573 |
| Zakrzewski Joseph S | Director |
Nov 27 '24 |
Buy |
1.40 |
2,000 |
2,800 |
125,199 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):